Loading...

IART INTEGRA LIFESCIENCES HOLDINGS CORP Legal Disputes 8-K Filing

NTGR

RT

INTEGRA LIFESCIENCES HOLDINGS CORP

(IART)

2025 8-K

Show Summary

Summary

Debt-Equity Swaps

Financial Statements

Earnings Announcement

FDA Warning Letter

Severance Program

Q3 2024 Results

CEO Appointment

Financial Results Announcement

Share Repurchase Agreement

Annual Meeting and Share Re...

Financial Results Announcement

Retirement and Appointment

Financial Results Announcement

Amendment to Filing

Agreement Amendment

Appointment of Director, Ch...

Acquisition Agreement

Financial Results Announcement

Share Repurchase Agreement

Financial Results and FDA W...

Appointment of CFO

Material Impairments

Annual Meeting of Stockholders

Financial Results

External Links:

Integra LifeSciences received a warning letter from the FDA regarding quality system issues at three facilities, but it does not restrict manufacturing or shipping and the company reaffirms its revenue guidance of $441 million to $451 million for Q4 2024.

AI Assistant

INTEGRA LIFESCIENCES HOLDINGS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.